Immediate Impact
1 from Science/Nature 52 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
Works of Joseph Maakaron being referenced
Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis
2023
Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Joseph Maakaron | 244 | 117 | 69 | 131 | 62 | 442 | |
| Lori A. Leslie | 240 | 48 | 119 | 83 | 70 | 390 | |
| Folashade Otegbeye | 301 | 126 | 36 | 228 | 57 | 493 | |
| Muhammad Husnain | 217 | 68 | 38 | 62 | 64 | 435 | |
| Masatoshi Sakurai | 112 | 194 | 111 | 61 | 67 | 462 | |
| Xing-Mei Cao | 212 | 174 | 34 | 184 | 32 | 494 | |
| Bénédicte Deau | 164 | 90 | 97 | 113 | 42 | 461 | |
| David A. Bond | 183 | 66 | 237 | 93 | 49 | 471 | |
| Eiko Hayase | 157 | 166 | 22 | 116 | 31 | 481 | |
| Huiying Qiu | 203 | 150 | 43 | 99 | 89 | 496 | |
| Jörg Faber | 190 | 107 | 43 | 104 | 30 | 454 |
All Works
Login with ORCID to disown or claim papers
Loading papers...